Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02581007 · OUTCOME

GVHD Incidence

Reduced Intensity Conditioning Transplant Using Haploidentical Donors · Source last updated 2023-04-27

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percentage of patients
Interval / dispersion
95% Confidence Interval
Time frame
100 days

What was measured

The number of participants that developed graft-versus-host-disease before or at 100 days after transplant

Groups in this outcome

Reduced-Intensity Mismatched Transplant

Fludarabine, Melphalan \& Post-transplant cyclophosphamide Fludarabine: fludarabine (30mg/m2) given every day starting on Day -6 through Day -2; Melphalan Cyclophosphamide: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4. peripheral blood stem cell transplant

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Reduced-Intensity Mismatched Transplant25

Reported measurements

Grades II to IV acute GVHD
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Reduced-Intensity Mismatched Transplant20Not reported837Not reported
Grades III to IV acute GVHD
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Reduced-Intensity Mismatched Transplant8Not reported222Not reported
Moderate chronic GVHD
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Reduced-Intensity Mismatched Transplant16Not reported533Not reported
Severe chronic GVHD
Values in percentage of patients · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Reduced-Intensity Mismatched Transplant12Not reported327Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        8
        upper Limit
        37
        value
        20
    title
    Grades II to IV acute GVHD
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        2
        upper Limit
        22
        value
        8
    title
    Grades III to IV acute GVHD
  3. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5
        upper Limit
        33
        value
        16
    title
    Moderate chronic GVHD
  4. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        3
        upper Limit
        27
        value
        12
    title
    Severe chronic GVHD
denoms
  1. counts
    1. group Id
      OG000
      value
      25
    units
    Participants
description
The number of participants that developed graft-versus-host-disease before or at 100 days after transplant
dispersion Type
95% Confidence Interval
groups
  1. description
    Fludarabine, Melphalan \& Post-transplant cyclophosphamide Fludarabine: fludarabine (30mg/m2) given every day starting on Day -6 through Day -2; Melphalan Cyclophosphamide: cyclophosphamide (50mg/kg) given every day starting on Day 3 through Day 4. peripheral blood stem cell transplant
    id
    OG000
    title
    Reduced-Intensity Mismatched Transplant
param Type
NUMBER
reporting Status
POSTED
time Frame
100 days
title
GVHD Incidence
type
SECONDARY
unit Of Measure
percentage of patients

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice